References and Notes
-
1a
Comprehensive Asymmetric Catalysis
Jacobsen EN.
Pfaltz A.
Yamamoto H.
Springer;
New York:
1999.
-
1b
Catalytic Asymmetric Synthesis
Ojima I.
Wiley-VCH;
New York:
2000.
2nd ed:
-
2a
Tsuji J.
Palladium Reagents and Catalysis
John Wiley & Sons;
Chichester:
2004.
-
2b
Negishi E.
Handbook of Organopalladium Chemistry for Organic Synthesis
Wiley;
Hoboken NJ:
2002.
-
2c
Heck RF.
Pd Reagents in Organic Synthesis
Academic;
New York:
1985.
-
2d
Tietze LF.
Ila H.
Bell HP.
Chem. Rev.
2004,
104:
3453
-
3a
Noyori R.
Angew. Chem. Int. Ed.
2002,
41:
2008
-
3b
Knowles WS.
Angew. Chem. Int. Ed.
2002,
41:
1998
-
3c
Rossen K.
Angew. Chem. Int. Ed.
2001,
40:
4611
-
3d
Tang W.
Zhang X.
Chem. Rev.
2003,
103:
3029
-
For reviews on the asymmetric hydrogenation of imines, see:
-
4a
Kobayashi S.
Ishitani H.
Chem. Rev.
1999,
99:
1069
-
4b
Brunel JM.
Recent Res. Dev. Org. Chem.
2003,
7:
155
-
4c
Liu P.
Jiang H.-F.
Chin. J. Org. Chem.
2004,
24:
1317
-
Recent literature on heterogeneous Pd asymmetric hydrogenation:
-
5a
Studer M.
Blaser H.-U.
Exner C.
Adv. Synth. Catal.
2003,
345:
45
-
5b
Tungler A.
Fogassy G.
J. Mol. Catal. A: Chem.
2001,
173:
231
-
5c
Blaser H.-U.
Indolese A.
Schnyder A.
Steiner H.
Studer M.
J. Mol. Catal. A: Chem.
2001,
173:
3
-
5d
Li C.
Catal. Rev.
2004,
46:
419
-
5e
Glorius F.
Spielkamp N.
Holle S.
Goddard R.
Lehmann CW.
Angew. Chem. Int. Ed.
2004,
43:
2850
-
5f
Raynor SA.
Thomas JM.
Raja R.
Johnson BFG.
Bell RG.
Mantle MD.
Chem. Commun.
2000,
1925
-
6a
Abe H.
Amii H.
Uneyama K.
Org. Lett.
2001,
3:
313
-
6b
Suzuki A.
Mae M.
Amii H.
Uneyama K.
J. Org. Chem.
2004,
69:
5132
- 7
Nanayakkara P.
Alper H.
Chem. Commun.
2003,
2384
- 8
Wang Y.-Q.
Lu S.-M.
Zhou Y.-G.
Org. Lett.
2005,
7:
3235
-
9a
Krzyzanowska B.
Stec WJ.
Synthesis
1982,
270
-
9b
Masumoto S.
Usuda H.
Suzuki M.
Kainai M.
Shibasaki M.
J. Am. Chem. Soc.
2003,
125:
5634
-
Asymmetric hydrogenation of N-diphenylphosphinyl imines:
-
10a Rh complex: Spindler F.
Blaser H.-U.
Adv. Synth. Catal.
2001,
343:
68
-
10b Ir complex: Jiang X.-B.
Minnaard AJ.
Hessen B.
Feringa BL.
Duchateau ALL.
Andrien JGO.
Boogers JAF.
de Vries JG.
Org. Lett.
2003,
5:
1503
-
Asymmetric reduction of N-diphenylphosphinyl imines without hydrogen:
-
11a
Yamada T.
Nagata T.
Sugi K.
Yorozu K.
Ikeno T.
Ohtsuka Y.
Miyazaki D.
Mukaiyama T.
Chem. Eur. J.
2003,
9:
4485
-
11b
Hutchins RO.
Magid AA.
Stercho YP.
Wambsgans A.
J. Org. Chem.
1987,
52:
702
-
11c
Lipshutz BH.
Shimizu H.
Angew. Chem. Int. Ed.
2004,
43:
2228
- 12
N-(Diphenylphosphinyl)amines 2 obtained by addition of diorganozinc to aldimines: Boezio AA.
Pytkowicz J.
Côté A.
Charette AB.
J. Am. Chem. Soc.
2003,
125:
14260
13 A series of additives were tested in the reaction of 1b: 3 Å MS (conversion: >95%, 96.4% ee), 5 Å MS (conversion: 72%, 96.4% ee), Na2SO4 (conversion: 64%, 96.4% ee).
14
Asymmetric Hydrogenation; Typical Procedure. (S)-SEGPHOS (2.9 mg, 0.0048 mmol) and Pd(CF3CO2)2 (1.3 mg, 0.004 mmol) were placed in a dried Schlenk tube under a nitrogen atmosphere, and degassed anhydrous acetone was added. The mixture was stirred at r.t. for 1 h. The solvent was removed under vacuum to give the catalyst. This catalyst was placed in a nitrogen-filled glove box and dissolved in anhyd TFE (1 mL). To a mixture of 1a and 4 Å MS, the catalyst solution was added, and then the mixture was transferred to an autoclave. The hydrogenation was performed at r.t. under H2 (1000 psi) for 8-12 h. The hydrogen was carefully released and the solvents were removed. Conversion was determined by 1H NMR spectroscopy. The ee was determined by HPLC after purification on silica gel (hexanes-EtOAc-Et3N, 1:2:0.02). The absolute configuration of 2a was determined by measurement of its optical rotation. N-Diphenylphosphinyl imines 1 were prepared according to the literature.
[9]
Racemates of N-(diphenylphosphinyl)amines were prepared by reduction of the corresponding imines using NaBH4 in THF. For the preparation of complexes and other experimental details, see reference 8.
15 Compound 1c: white solid. 1H NMR (400 MHz, CDCl3): δ = 2.95 (d, J = 1.8 Hz, 3 H), 7.12-7.17 (m, 2 H), 7.43-7.45 (m, 6 H), 7.94-7.99 (m, 4 H), 8.09-8.12 (m, 2 H). 13C NMR (100 MHz, CDCl3): δ = 23.1 (d, J = 12.3 Hz), 115.8 (d, J = 21.7 Hz), 128.6 (d, J = 12.3 Hz), 130.6 (d, J = 8.9 Hz), 131.7, 131.8, 134.8 (d, J = 130.2 Hz), 135.9 (d, J = 25.8 Hz), 165.7 (d, J = 252.7 Hz), 180.2 (d, J = 7.0 Hz). 31P NMR (162 MHz, CDCl3): δ = 19.1. HRMS (ESI): m/z calcd for C20H18FNOP [M + H+]: 338.1105; found: 338.1082.
Compound 1f: white solid. 1H NMR (400 MHz, CDCl3): δ = 2.95 (d, J = 2.1 Hz, 3 H), 3.88 (s, 3 H), 7.10 (m, 1 H), 7.39-7.46 (m, 7 H), 7.64 (d, J = 2.4 Hz, 2 H), 7.95-8.00 (m, 4 H). 13C NMR (100 MHz, CDCl3): δ = 23.3 (d, J = 12.4 Hz), 55.6, 113.6, 117.9, 120.7, 128.6 (d, J = 12.4 Hz), 129.7, 131.6, 131.7 (d, J = 9.0 Hz), 134.8 (d, J = 130.3 Hz), 141.0 (d, J = 23.9 Hz), 159.8, 181.5 (d, J = 7.5 Hz). 31P NMR (162 MHz, CDCl3): δ = 19.3. HRMS (ESI): m/z calcd for C21H21NO2P [M + H+]: 350.1304; found: 350.1297.
Compound 1g: white solid. 1H NMR (400 MHz, CDCl3): δ = 2.89 (d, J = 2.0 Hz, 3 H), 3.82 (d, J = 2.4 Hz, 3 H), 6.93 (d, J = 8.3 Hz, 1 H), 7.00 (s, 1 H), 7.40-7.45 (m, 7 H), 7.63 (dd, J = 1.7, 7.6 Hz, 1 H), 7.93-7.99 (m, 4 H). 13C NMR (100 MHz, CDCl3): δ = 28.3 (d, J = 13.6 Hz), 55.5, 111.6, 120.6, 128.4 (d, J = 12.3 Hz), 129.9, 131.4, 131.8 (d, J = 8.9 Hz), 132.3, 134.9 (d, J = 129.2 Hz), 158.0, 186.0 (d, J = 7.6 Hz). 31P NMR (162 MHz, CDCl3): δ = 18.5. HRMS (ESI): m/z calcd for C21H21NO2P [M + H+]: 350.1304; found: 350.1288.
Compound 2a: white solid; 95.3% ee (R); [α]D
26 +38.3 (c 0.54, EtOH); R
f
0.14 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 20:80, 1.0 mL/min, 254 nm): t
R 12.9 min (R), t
R 24.4 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.58 (d, J = 6.7 Hz, 3 H), 3.17 (dd, J = 5.9, 9.1 Hz, 1 H), 4.36-4.43 (m, 1 H), 7.26-7.45 (m, 11 H), 7.80-7.85 (m, 2 H), 7.89-7.93 (m, 2 H).
Compound 2b: white solid; 96.6% ee (S); [α]D
8 -66.5 (c 1.08, MeOH); R
f
0.22 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80-20, 1.0 mL/min, 254 nm): t
R 11.4 min (R), t
R 15.8 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.56 (d, J = 6.8 Hz, 3 H), 2.34 (s, 3 H), 3.14-3.17 (m, 1 H), 4.32-4.39 (m, 1 H), 7.15 (dd, J = 8.0, 20.4 Hz, 4 H), 7.37-7.48 (m, 6 H), 7.81-7.91 (m, 4 H).
Compound 2c: white solid; 94.0% ee (S); [α]D
8 -41.9 (c 1.04, MeOH); R
f
0.18 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 10.0 min (R), t
R 27.0 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.55 (d, J = 6.8 Hz, 3 H), 3.11 (dd, J = 5.9, 9.2 Hz, 1 H), 4.35-4.42 (m, 1 H), 6.98 (t, J = 8.7 Hz, 2 H), 7.23-7.25 (m, 2 H), 7.36-7.37 (m, 2 H), 7.44-7.46 (m, 4 H), 7.78-7.81 (m, 2 H), 7.88-7.92 (m, 2 H).
Compound 2d: white solid; 94.2% ee (S); [α]D
8 -73.4 (c 1.14, MeOH); R
f
0.33 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 11.4 min (R), t
R 26.3 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.55 (d, J = 6.8 Hz, 3 H), 3.17 (dd, J = 5.7, 9.5 Hz, 1 H), 4.33-4.40 (m, 1 H), 7.24 (dd, J = 8.5, 23.0 Hz, 4 H), 7.37-7.47 (m, 6 H), 7.79 (dd, J = 7.0, 12.0, 2 H), 7.90 (dd, J = 6.9, 11.9 Hz, 2 H).
Compound 2e: white solid; 96.0% ee (S); [α]D
8 -66.4 (c 1.30, MeOH); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 15.9 min (R), t
R 26.8 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.55 (d, J = 6.7 Hz, 3 H), 3.12 (dd, J = 5.9, 9.4 Hz, 1 H), 3.80 (s, 3 H), 4.31-4.41 (m, 1 H), 6.85 (d, J = 8.7 Hz, 2 H), 7.21 (d, J = 8.7 Hz, 2 H), 7.37-7.48 (m, 6 H), 7.81-7.91 (m, 4 H).
Compound 2f: white solid; 96.0% ee (S); [α]D
8 -52.1 (c 1.32, MeOH); R
f
0.38 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 14.5 min (R), t
R 29.4 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.57 (d, J = 6.8 Hz, 3 H), 3.22 (dd, J = 5.9, 9.5 Hz, 1 H), 3.78 (s, 3 H), 4.31-4.39 (m, 1 H), 6.82-6.88 (m, 3 H), 7.21-7.23 (m, 1 H), 7.36-7.47 (m, 6 H), 7.80-7.93 (m, 4 H).
Compound 2g: white solid; 98.6% ee (S); [α]D
8 -22.1 (c 1.13, MeOH); R
f
0.33 (PE-EtOAc, 1:1). HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 11.9 min (R), t
R 21.3 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.50 (d, J = 6.8 Hz, 3 H), 3.69 (s, 3 H), 3.87 (dd, J = 8.0, 10.5 Hz, 1 H), 4.36-4.43 (m, 1 H), 6.78-6.82 (m, 2 H), 6.97 (s, 1 H), 7.19 (t, J = 7.7 Hz, 1 H), 7.33-7.38 (m, 6 H), 7.72 (dd, J = 7.3, 11.9 Hz, 2 H), 7.79 (dd, J = 7.1, 11.8 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ = 25.1, 49.6, 55.4, 111.2, 121.0, 128.3 (d, J = 7.0 Hz), 128.5, 131.7, 131.8, 128.1 (d, J = 108.6 Hz), 131.7, 131.8, 132.0 (d, J = 9.3 Hz), 132.8 (d, J = 9.4 Hz), 133.0, 133.1, 133.8 (d, J = 119.7 Hz), 157.0. 31P NMR (162 MHz, CDCl3): δ = 22.9. HRMS (ESI): m/z calcd for C21H23NO2P [M + H+], 352.1461; found, 352.1451.
Compound 2h: white solid; 86.7% ee (S); [α]D
8 -38.5 (c 1.26, MeOH); R
f
0.31 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 9.6 min (R), t
R 17.7 min (S). 1H NMR (400 MHz, CDCl3): δ = 0.79 (t, J = 7.4 Hz, 3 H), 1.80-1.89 (m, 1 H), 1.97-2.04 (m, 1 H), 3.25 (dd, J = 6.4, 9.4 Hz, 1 H), 4.08-4.11 (m, 1 H), 7.14-7.16 (m, 2 H), 7.23-7.33 (m, 5 H), 7.42-7.44 (m, 4 H), 7.73-7.87 (m, 4 H).
Compound 2i: white solid; 92.8% ee (S); [α]D
8 -77.8 (c 1.02, MeOH); R
f
0.39 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 21.6 min (R), t
R 27.7 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.66 (d, J = 6.7 Hz, 3 H), 3.27-3.31 (m, 1 H), 4.51-4.61 (m, 1 H), 7.32-7.33 (m, 2 H), 7.43-7.48 (m, 7 H), 7.65 (s, 1 H), 7.80-7.83 (m, 5 H), 7.93 (m, 2 H).
Compound 2j: white solid, 87.0% ee (S), [α]D
8 -42.1 (c 0.60, CH2Cl2); R
f
0.34 (PE-CH2Cl2,1:4); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t
R 12.1 min (R), t
R 17.0 min (S). 1H NMR (400 MHz, CDCl3): δ = 1.60 (d, J = 6.8 Hz, 3 H), 3.19 (dd, J = 6.6, 10.3 Hz, 1 H), 4.38-4.44 (m, 1 H), 6.13 (d, J = 3.2 Hz, 1 H), 6.28 (dd, J = 1.9, 3.2 Hz, 1 H), 7.35 (m, 1 H), 7.42-7.49 (m, 6 H), 7.87-7.95 (m, 4 H).